Clinical Trial Update: Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated Velcade (bortezomib) in patients with relapsed follicular lymphoma; the trial completed and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Relapsed Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2013-04-29